Table 1.
Main thermosensitive injectable hydrogel and drug delivery system.
| Hydrogel | Drug | Cell line (in vitro) | Cancer (in vivo) | Characteristics and applications | References |
|---|---|---|---|---|---|
| Chitosan/glycerophosphate (CS/GP) | Indocyanine green (ICG) | Hepatocellular carcinoma (HCC) | – | Hydrogel loaded with ICG is a feasible agent for fluorescence imaging and drug delivery. It forms in situ compact gel and has a good ability for filling vessels | Salis et al., 2015 |
| CS/GP | DOXorubicin (DOX) | H22 and SMMC 7721 (hepatoma) | Hepatoma | This in situ gelling thermosensitive hydrogel is capable of drug delivery to tumor tissue constantly and efficiently | Ren et al., 2016 |
| Hyaluronic acid (HA) and Pluronic F127 (PF127) | DOXorubicin (DOX) and Docetaxel (DOC) | CT-26 (colorectal carcinoma) | Colorectal carcinoma | Thermosensitive hydrogels loaded with DOX and DOX has a good potential for dual drug delivery, which efficiently enhanced cancer management with minimal side effects | Sheu et al., 2016 |
| PLGA-PEG-PLGA | PLK1shRNA/PEI-Lys and DOX | Saos-2 and MG63 (osteosarcoma) | Osteosarcoma | Localized hydrogel with RNA and DOX co-loaded is promising for efficient clinical management of osteosarcoma | Ma et al., 2014 |
| PLGA | Paclitaxel (PTX) | M234-p (mammary tumor) | mammary tumor | Four times the efficacy of existing commercial drugs | Pesoa et al., 2018 |
| POR–PEG–PCL | fluorescence tag | HepG2 (hepatoma) | hepatoma | Good safety and biocompatibility in vitro and in vivo | Dong et al., 2016 |
| PCL-PTSUO-PEG | TNP/DOX/ZnPC | 5637 (bladder cancer cells) | Bladder carcinoma | Double insurance from TNP/ZnPC and TNP/DOX loaded in hydrogel for the management of bladder carcinoma | Huang et al., 2018 |
| PEG–PCL–PEG, PECE | PTX | 4T1 (breast cancer) | Breast cancer | Great antitumor effect and wound healing promotion. | Lei et al., 2012 |
| PECT | PTX | MCF-7 | Breast cancer | High concentration in tumor tissue for 21 days | Lin et al., 2016 |